Howard L McLeod

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc Multivariate methods and software for association mapping in dose-response genome-wide association studies
    Chad C Brown
    Department of Statistics, North Carolina State University, Raleigh, NC, USA
    BioData Min 5:21. 2012
  2. doi request reprint Cancer pharmacogenomics: early promise, but concerted effort needed
    Howard L McLeod
    Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599, USA
    Science 339:1563-6. 2013
  3. pmc Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741
    Howard L McLeod
    University of North Carolina Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599 7360, USA
    J Clin Oncol 28:3227-33. 2010
  4. pmc Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial
    Hanna K Sanoff
    Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 27:4109-15. 2009
  5. doi request reprint Pharmacogenetics of breast cancer therapies
    Daniel L Hertz
    UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, NC 27599, USA
    Breast 18:S59-63. 2009
  6. pmc Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines
    VENITA GRESHAM WATSON
    UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Mol Cancer Ther 10:1839-45. 2011
  7. pmc Pharmacogenomic characterization of US FDA-approved cytotoxic drugs
    Eric J Peters
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599 7361, USA
    Pharmacogenomics 12:1407-15. 2011
  8. doi request reprint Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care
    Tejinder K Rakhra-Burris
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7361, USA
    Pharmacogenomics 11:13-21. 2010
  9. doi request reprint Making pharmacogenetic testing a reality in a community pharmacy
    Shanna K O'Connor
    Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, USA
    J Am Pharm Assoc (2003) 52:e259-65. 2012
  10. doi request reprint Assessing the utility of whole genome amplified DNA as a template for DMET Plus array
    Yi Jing He
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC, USA
    Clin Chem Lab Med 50:1329-34. 2012

Research Grants

  1. Pharmacogenetics advanced colorectal cancer
    Howard McLeod; Fiscal Year: 2004
  2. Functional Polymorphism Analysis in Drug Pathways
    Howard McLeod; Fiscal Year: 2007

Collaborators

Detail Information

Publications53

  1. pmc Multivariate methods and software for association mapping in dose-response genome-wide association studies
    Chad C Brown
    Department of Statistics, North Carolina State University, Raleigh, NC, USA
    BioData Min 5:21. 2012
    ..However, previous studies may have over-simplified the complex differences in dose-response profiles between genotypes, resulting in a loss of power...
  2. doi request reprint Cancer pharmacogenomics: early promise, but concerted effort needed
    Howard L McLeod
    Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599, USA
    Science 339:1563-6. 2013
    ....
  3. pmc Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741
    Howard L McLeod
    University of North Carolina Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599 7360, USA
    J Clin Oncol 28:3227-33. 2010
    ..Pharmacogenetics identifies the likelihood of adverse events or response based on variants in genes involved in drug transport, metabolism, and cellular targets...
  4. pmc Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial
    Hanna K Sanoff
    Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 27:4109-15. 2009
    ..A subgroup analysis of a multisite National Cancer Institute-sponsored trial (N9741) was performed comparing outcomes of black and white patients with metastatic CRC receiving uniform treatment...
  5. doi request reprint Pharmacogenetics of breast cancer therapies
    Daniel L Hertz
    UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, NC 27599, USA
    Breast 18:S59-63. 2009
    ..The other gene that will be discussed in the review is cytochrome P450 2D6 (CYP2D6; gene: CYP2D6), which has many genetic variants that impair the bioactivation and effectiveness of tamoxifen therapy...
  6. pmc Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines
    VENITA GRESHAM WATSON
    UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Mol Cancer Ther 10:1839-45. 2011
    ..The remaining 3 QTLs (chromosomes 6 and 20) are considered specific to camptothecin-induced cytotoxicity. Finally, 8 QTLs were identified, which were unique to the indenoisoquinolines...
  7. pmc Pharmacogenomic characterization of US FDA-approved cytotoxic drugs
    Eric J Peters
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599 7361, USA
    Pharmacogenomics 12:1407-15. 2011
    ..Individualization of cancer chemotherapy based on the patient's genetic makeup holds promise for reducing side effects and improving efficacy. However, the relative contribution of genetics to drug response is unknown...
  8. doi request reprint Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care
    Tejinder K Rakhra-Burris
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7361, USA
    Pharmacogenomics 11:13-21. 2010
    ..IPIT Investigators are actively incorporating a pharmacogenomics curriculum into existing teaching programs at all levels...
  9. doi request reprint Making pharmacogenetic testing a reality in a community pharmacy
    Shanna K O'Connor
    Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, USA
    J Am Pharm Assoc (2003) 52:e259-65. 2012
    ..To provide information for community pharmacies considering implementation of a pharmacogenetic testing service...
  10. doi request reprint Assessing the utility of whole genome amplified DNA as a template for DMET Plus array
    Yi Jing He
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC, USA
    Clin Chem Lab Med 50:1329-34. 2012
    ..Multiple displacement amplification (MDA)-based whole genome amplification is an in vitro technique that permits the genetic analysis of limited amounts of high molecular weight genomic DNA (gDNA)...
  11. pmc CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel
    Daniel L Hertz
    UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, 120 Mason Farm Road, CB 7361, Chapel Hill, NC 27599, USA
    Breast Cancer Res Treat 134:401-10. 2012
    ..Patients carrying CYP2C8*3 are more likely to achieve clinical complete response from neoadjuvant paclitaxel treatment, but may also be at increased risk of experiencing severe peripheral neurotoxicity...
  12. doi request reprint Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy
    Stefanie D Krens
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, 120 Mason Farm Road, CB 7361, Chapel Hill, NC 27599, USA
    Pharmacogenomics 14:555-74. 2013
    ..The clinical implementation of pharmacogenetics, enzyme probes or therapeutic drug monitoring could enable clinicians to personalize taxane treatment to enhance efficacy and/or limit toxicity...
  13. pmc Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan
    Janelle M Hoskins
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Genetic Medicine Building, Chapel Hill, NC 27599 7360, USA
    Pharmacogenomics 10:1139-46. 2009
    ..The present study was conducted to evaluate previous gene associations using an independent sample of patients receiving irinotecan...
  14. pmc Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis
    Fabienne Thomas
    University of North Carolina, Chapel Hill, NC, USA
    Pharmacogenomics 11:1751-6. 2010
    ..Genotyping methods for the TYMS 5'-UTR polymorphisms have typically involved visualizing PCR and RFLP products on agarose gels. This article describes the use of a robust capillary electrophoresis assay for TYMS 5'-UTR genotyping...
  15. ncbi request reprint Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity
    J Todd Auman
    UNC Institute for Pharmacogenomics and Individualized Therapy, Chapel Hill, North Carolina 27599 7360, USA
    Drug Metab Rev 40:303-15. 2008
    ..This review focuses on pharmacogenomics studies conducted to gain insight into the molecular determinants of chemosensitivity to cancer chemotherapeutics...
  16. pmc Identification and replication of loci involved in camptothecin-induced cytotoxicity using CEPH pedigrees
    VENITA GRESHAM WATSON
    Division of Pharmacotherapy and Experimental Therapeutics, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS ONE 6:e17561. 2011
    ....
  17. pmc Tamoxifen and CYP2D6: a contradiction of data
    Daniel L Hertz
    UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 17:620-30. 2012
    ..Future association studies on the link between CYP2D6 genotype and tamoxifen treatment efficacy should account for combination therapy and CYP2D6 inhibition, and interrogate as many CYP2D6 alleles as possible...
  18. pmc Race does not explain genetic heterogeneity in pharmacogenomic pathways
    Jane L Yen-Revollo
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, Campus Box 7360, 3203 Kerr Hall, Chapel Hill, NC 27599 7360, USA
    Pharmacogenomics 9:1639-45. 2008
    ....
  19. doi request reprint Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity
    Eric J Peters
    Schools of Pharmacy and Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
    Pharmacogenet Genomics 19:399-401. 2009
    ..Furthermore, they provide additional biological validation of the relevance of LCLs as a model for pharmacogenomic gene discovery in cancer chemotherapy...
  20. doi request reprint Pharmacogenomic contribution to drug response
    Roshawn G Watson
    UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7361, USA
    Cancer J 17:80-8. 2011
    ..Ultimately, integration of both pharmacogenomic and clinical characteristics can provide powerful predictive tools for stratifying responders from nonresponders and identifying patients at increased risk for toxicity...
  21. ncbi request reprint Applications of genomic tools to colorectal cancer therapeutics
    J Todd Auman
    UNC Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7360, USA
    Curr Opin Mol Ther 10:548-54. 2008
    ..Future research toward integrating genomic information with clinical and histopathological data is expected to lead to improved therapeutic management of colorectal cancer...
  22. pmc Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma
    Benjamin R Tan
    Washington University School of Medicine, St Louis, MO, USA
    J Clin Oncol 29:875-83. 2011
    ..We conducted a prospective single-institution phase II study using TYMS genotyping to direct neoadjuvant CRT for patients with rectal cancer...
  23. doi request reprint Gastric cancer pharmacogenetics: progress or old tripe?
    Jai N Patel
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599 7361, USA
    Pharmacogenomics 14:1053-64. 2013
    ....
  24. doi request reprint Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity
    Daniel L Hertz
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Hum Genet 58:346-52. 2013
    ..Use of pre-treatment pharmacogenetic testing will someday enable clinicians to make individualized therapy decisions about aggressiveness, drug selection and dose, improving treatment outcomes for cancer patients. ..
  25. doi request reprint Applying the genome to national drug formulary policy in the developing world
    Mary W Roederer
    Institute of Pharmacogenomics and Individualized Therapy, UNC Eshelman School of Pharmacy, Chapel Hill, NC 27599 7361, USA
    Pharmacogenomics 11:633-6. 2010
    ..The goal should always be optimizing therapy for each individual patient, but pharmacogenetics can be useful now and essential in the future for the developing world...
  26. pmc Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy
    Roshawn G Watson
    Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Eur J Cancer 46:3358-64. 2010
    ....
  27. pmc Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study
    William J Irvin
    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Clin Oncol 29:3232-9. 2011
    ....
  28. pmc Copy number variants in pharmacogenetic genes
    Yijing He
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Genetic Medicine Building, 120 Mason Farm Rd, Chapel Hill, NC 27599 7360, USA
    Trends Mol Med 17:244-51. 2011
    ....
  29. doi request reprint Colorectal cancer cell lines lack the molecular heterogeneity of clinical colorectal tumors
    James Todd Auman
    UNC Institute of Pharmacogenomics and Individualized Therapy, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, 27599, USA
    Clin Colorectal Cancer 9:40-7. 2010
    ..However, it is not clear to what extent available CRC cell lines reflect the molecular heterogeneity observed in clinical colorectal tumors...
  30. doi request reprint Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial
    Daniel E Jonas
    Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, 5034 Old Clinic Building, CB 7110, Chapel Hill, NC 27599, USA
    Pharmacogenomics 14:1593-603. 2013
    ..This study aimed to assess the effectiveness of genotype-guided warfarin dosing...
  31. pmc Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity
    Brian C Jensen
    UNC School of Medicine, Division of Cardiology, 160 Dental Circle, CB 7075, Chapel Hill, NC 27599 7075, USA
    Pharmacogenomics 14:205-13. 2013
    ..In this commentary we indicate a need for more powerful means to identify risk prospectively, and suggest that broad pharmacogenomic approaches may be fruitful...
  32. doi request reprint Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy
    Shanna K O'Connor
    Division of Pharmacy Practice and Experiential Education CB 7574, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7574, USA
    Pharmacogenomics 13:955-62. 2012
    ..An institutional review board-approved protocol for a clopidogrel pharmacogenetic program in a community pharmacy was developed to address feasibility and evaluate the pilot program...
  33. pmc A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT
    Chad C Brown
    Department of Statistics, North Carolina State University, Raleigh, North Carolina 27695 7566, USA
    Pharmacogenet Genomics 22:796-802. 2012
    ..Recently, lymphoblastoid cell lines (LCLs) have emerged as an innovative model system for mapping gene variants that predict the dose response to chemotherapy drugs...
  34. pmc Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians
    Kevin C Brown
    University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, 3202 Kerr Hall, Chapel Hill, NC 27599 7569, USA
    Pharmacogenomics 13:113-21. 2012
    ..Genetic polymorphisms have the potential to influence drug metabolism and vary among ethnic groups. This study evaluated the correlation of genetic polymorphisms with nevirapine pharmacokinetics exposure in Malawians...
  35. pmc Platinum neurotoxicity pharmacogenetics
    Sarah R McWhinney
    School of Pharmacy, Institute for Pharmacogenomics and Individualized Therapy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, Campus Box 7360, 3203 Kerr Hall, Chapel Hill, NC 27599 7360, USA
    Mol Cancer Ther 8:10-6. 2009
    ..These data have the potential for broad clinical implications if mechanistic associations lead to the development of toxicity modulators to minimize the noxious sequelae of platinum chemotherapy...
  36. pmc Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms
    Michael R Langley
    Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7525, USA
    J Mol Diagn 11:216-25. 2009
    ..The predicted doses from both the Washington University and UCSF algorithms demonstrated the best correlation with actual warfarin doses...
  37. doi request reprint Pharmacogenetics and rational drug use around the world
    Mary W Roederer
    Institute of Pharmacogenomics and Individualized Therapy, UNC Eshelman School of Pharmacy, CB 7361, 120 Mason Farm Road, 1092 Genetic Medicine Building, Chapel Hill, NC 27599 7361, USA
    Pharmacogenomics 12:897-905. 2011
    ..While there are many unanswered questions, systematically incorporating pharmacogenetics at the national formulary level promises to improve global drug use...
  38. pmc Using germline genotype in cancer pharmacogenetic studies
    Sarah R McWhinney
    Lineberger Comprehensive Cancer Center, University of North Carolna, Chapel Hill, Campus Box 7360, Kerr Hall, Chapel Hill, NC 27599 7360, USA
    Pharmacogenomics 10:489-93. 2009
    ..This use of germline DNA offers great opportunities for the implementation of individualized therapy...
  39. pmc Systems pharmacology assessment of the 5-fluorouracil pathway
    Filipe A Muhale
    UNC Institute for Pharmacogenomics and Individualized Therapy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7361, USA
    Pharmacogenomics 12:341-50. 2011
    ..To assess the impact of the 5-fluorouracil (5-FU) drug-pathway genes on cytotoxicity, and determine whether loss-of-function analyses coupled with functional assays can help prioritize pharmacogenomic candidate genes...
  40. pmc Implications of genome-wide association studies in cancer therapeutics
    Jai N Patel
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC, 27599 7361, USA
    Br J Clin Pharmacol 76:370-80. 2013
    ..Given the large heterogeneity in response to cancer therapeutics, novel methods of identifying mechanisms and biology of variable drug response and ultimately treatment individualization will be indispensable...
  41. doi request reprint Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
    Jane L Yen-Revollo
    University of North Carolina Schools of Pharmacy and Medicine, Lineberger Comprehensive Cancer Center, Institute for Pharmacogenomics and Individualized Therapy, Chapel Hill, North Carolina 27599 7360, USA
    Clin Cancer Res 14:8-13. 2008
    ....
  42. pmc Genomewide analysis of inherited variation associated with phosphorylation of PI3K/AKT/mTOR signaling proteins
    Janna E Hutz
    Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS ONE 6:e24873. 2011
    ....
  43. pmc Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome
    Janelle M Hoskins
    Division of Pharmacotherapy and Experimental Therapeutics, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS ONE 7:e41954. 2012
    ..As the CRC risk SNPs may also influence disease outcome, thus in this study, we evaluated whether they influence patient survival...
  44. pmc Genomics: applications in mechanism elucidation
    Venita Gresham
    UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, NC 27599 7360, USA
    Adv Drug Deliv Rev 61:369-74. 2009
    ..Genomic strategies have made impressive advances in defining a more global view of drug action and are expected to increasingly be used as a complimentary tool in drug discovery and development...
  45. doi request reprint CYP2D6 and tamoxifen: DNA matters in breast cancer
    Janelle M Hoskins
    UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, 27599, North Carolina, USA
    Nat Rev Cancer 9:576-86. 2009
    ..Here we review the existing data that relate CYP2D6 genotypes to response to tamoxifen and discuss whether the analysis of the CYP2D6 genotype might be an early example of a pharmacogenetic tool for optimizing breast cancer therapy...
  46. pmc Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation
    James Todd Auman
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, Chapel Hill, NC 27599 7360, United States
    Eur J Cancer 44:1754-60. 2008
    ..Celecoxib pre-treatment for 7 d in vivo is associated with alterations in colorectal adenocarcinoma gene expression which are suggestive of diminished cellular proliferation...
  47. doi request reprint Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations
    Kyle J Ellis
    Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, CB 7569, Kerr Hall, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 27569, USA
    Pharmacogenomics 10:1799-817. 2009
    ..Future studies remain necessary to develop effective personalized therapeutic strategies for CYP2C19 variant allele carriers and other individuals at risk for clopidogrel nonresponsiveness...
  48. doi request reprint Clinically relevant cancer biomarkers and pharmacogenetic assays
    Jai N Patel
    Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA UNC Institute for Pharmacogenomics and Individualized Therapy, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA
    J Oncol Pharm Pract 20:65-72. 2014
    ..While the literature regarding drug-gene associations and therapeutic implications is often robust, reviews regarding clinical assay availability and profiling methodologies of commonly used cancer biomarkers are often lacking...
  49. ncbi request reprint UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters
    Janelle M Hoskins
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599 7360, USA
    J Natl Cancer Inst 99:1290-5. 2007
    ..The risk of experiencing irinotecan-induced hematologic toxicity for patients with a UGT1A1*28/*28 genotype thus appears to be a function of the dose of irinotecan administered...
  50. doi request reprint Economic opportunities and challenges for pharmacogenomics
    Patricia A Deverka
    UNC Institute for Pharmacogenomics and Individualized Therapy, Department of Health Policy and Management, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Annu Rev Pharmacol Toxicol 50:423-37. 2010
    ....
  51. doi request reprint Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application
    Soo Youn Lee
    Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Pathol 223:15-27. 2011
    ..We will discuss the current level of evidence, if the current pharmacogenetic tests are appropriate for clinical application, and how to integrate the pharmacogenomic information into routine clinical practice...
  52. ncbi request reprint Should DPD analysis be required prior to prescribing fluoropyrimidines?
    Jane L Yen
    Department of Pharmacotherapy and Experimental Therapeutics, University of North Carolina School of Pharmacy and the UNC Institute for Pharmacogenomics and Individualized Therapy, Chapel Hill, NC 27599 7360, USA
    Eur J Cancer 43:1011-6. 2007
    ....
  53. doi request reprint Biomarkers for response to neoadjuvant chemoradiation for rectal cancer
    Jeffrey G Kuremsky
    Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599 7360, USA
    Int J Radiat Oncol Biol Phys 74:673-88. 2009
    ..Epidermal growth factor receptor, thymidylate synthase, and p21 should be evaluated in larger prospective clinical trials for their ability to guide preoperative therapy choices in LARC...

Research Grants2

  1. Pharmacogenetics advanced colorectal cancer
    Howard McLeod; Fiscal Year: 2004
    ..These aims provide a comprehensive framework for our strategy to provide the first prospective information on the integration of pharmacogenetic information into the selection of therapy for advanced colorectal cancer. ..
  2. Functional Polymorphism Analysis in Drug Pathways
    Howard McLeod; Fiscal Year: 2007
    ..This approach is allowing us to continue to make strong progress in our understanding of the role of genes in pharmacologic response. ..